Prevalence of type 2 diabetes (T2D) and glucose-lowering treatment in the Age, Gene/Environment Susceptibility-Reykjavik Study, 2002–2006
| AGES-Reykjavik Study | Men | Women | Men and women | Percentage of total T2D |
| Total T2D at baseline, % (n) | 16.3 (358) | 9.5 (281) | 12.4 (639) | 100 |
| Diagnosed at study entry, % (n) | 5.1 (113) | 2.8 (84) | 3.8 (197) | 31 |
| With prevalent T2D at study entry, % (n) | 11.2 (245) | 6.7 (197) | 8.6 (442) | 69 |
| Mean T2D duration, years (±SD) | 10.7 (±10.0) | |||
| Glucose-lowering treatment in prevalent T2D | ||||
| On special diet only, % (n) | 23.3 (57) | 34.5 (68) | ||
| On diabetic medication, % (n) | 76.7 (188) | 65.5 (129) | ||
| Using one drug, % (n) | 43.7 (107) | 40.1 (79) | ||
| Using two drugs, % (n) | 25.7 (63) | 19.8 (39) | ||
| Using three drugs, % (n) | 6.9 (17) | 4.6 (9) | ||
| Using four drugs, % (n) | 0.4 (1) | 1.0 (2) | ||